Amid Hype, Questions Remain About Data Usage, FDA Regulation of Consumer Genomics Services | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
Over the past week, two competing consumer genomics services offered by Decode Genetics and by privately held startup 23andMe were officially launched amid much hype and media attention, but questions remain about how the firms will make money off these services, if insurance companies will cover the services, and whether the US Food and Drug Administration will regulate them.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.